Your Health, We Care
Release date: 2024-08-15 17:08:20 Recommended: 155
As a highly selective RET inhibitor, Selpercatinib can effectively block the RET signaling pathway. It is primarily used for the treatment of RET fusion-positive solid tumors. Patients include adults and adolescents over 12 years of age.
The Bangladesh Everest version of Selpercatinib is 40mg*30 capsules, and the price is about 2,200 yuan per box; The Lucius version of Selpercatinib is 40mg*120 capsules, and the price is about 3375 yuan per box, and the price given is for reference only.
Selpercatinib is a targeted therapy that needs to be used under the guidance of a medical professional. The doctor will determine the most appropriate treatment plan based on the patient's health status, genetic test results, and recent medications. During the treatment, patients should take their medications on time and in accordance with the doctor's instructions.
Many patients are concerned about the efficacy of Selpercatinib, based on the results of clinical trial studies:
Among the 144 patients who received anti-PD-1 or anti-PD-L1 and platinum-based chemotherapy at the same time or successively, the objective response rate (ORR) was 63%, and the disease was significantly improved and controlled. The median duration of response (DOR) was 28.6 months, indicating that the patient's condition remained stable or improving for such a long time.
Of the 247 such patients, 16 were detected with measurable central nervous system (CNS) metastases at baseline. Fourteen patients experienced shrinkage or control of intracranial lesions, and 39% of them achieved or exceeded 12 months of intracranial remission.
In patients with cholangiocarcinoma, the most common adverse effects (incidence ≥20%) with Selpercatinib include the following:
Hyperphosphatemia is a condition in which phosphate levels in the blood are elevated, which can trigger muscle cramps, bone pain, and even negatively affect the kidneys. This adverse effect needs to be monitored by regular testing of blood phosphate levels and may need to be managed with dietary modifications or medications.
Patients may experience significant hair thinning or loss during treatment, which may have an impact on the patient's physical appearance and psychological state. Some patients may choose to wear a wig or take other cosmetic measures to cope with this change.
[Warm tips] During the period of taking Selpercatinib, patients should pay close attention to the changes in their health status. In case of any physical discomfort or abnormal reaction, you should seek medical attention immediately and take appropriate medical measures.
